REFRENCES
1. Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia.Hematology Am Soc Hematol Educ Program. 2016;2016(1):580-588.
2. Karrman K, Johansson B. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2017;56(2):89-116.
3. Doerrenberg M, Kloetgen A, Hezaveh K, et al. T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases. Genes Chromosomes Cancer.2017;56(2):159-167.
4. Tao J, Valderrama E, Kahn L. Congenital acute T lymphoblastic leukaemia: report of a case with immunohistochemical and molecular characterisation. Journal of Clinical Pathology.2000;53(2):150-152.
5. Salzer WL, Jones TL, Devidas M, et al. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children’s Oncology Group. Pediatr Blood Cancer.2015;62(3):414-418.
6. Szmit Z, Gorczynska E, Krol A, et al. Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD. Bone Marrow Transplant. 2020;55(11):2138-2146.
7. Teachey DT, O’Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children.Blood. 2020;135(3):159-166.
8. Muffly L, Larson RA. Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children’s Oncology Group incorporating nelarabine into front-line therapy. Transl Pediatr. 2012;1(2):120-122.
9. Winter SS, Dunsmore KP, Devidas M, et al. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018;36(29):2926-2934.
10. Dunsmore KP, Winter S, Devidas M, et al. COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.Journal of Clinical Oncology. 2018;36(15_suppl):10500-10500.
11. Cooper TM. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag. 2007;3(6):1135-1141.
12. Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Expert Rev Hematol. 2017;10(1):1-8.
13. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood. 1994;84(6):1737-1746.
14. Katherine Tarlock TA, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Tiffany Hylkema, Jenny L. Smith, Julia E. Maxson, Soheil Meshinchi. Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia. Blood. 2020;135:1603-1606.
15. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. New England Journal of Medicine. 2013;368(19):1781-1790.